IDVOther than small business
IDC (multiple-award IDV) 75N91019D00012IIT RESEARCH INSTITUTE
Overview
Award facts
- Obligated on orders under this IDV
- $2.27M
- $2,270,972 across 3 orders
- Period of performance
- From Jan 23, 2019
- Modifications
- 7
- Latest action Dec 17, 2024
- Contract type
- IDC (multiple-award IDV)
- PIID 75N91019D00012
Description of requirement
PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS (POP: 1/25/2019-1/24/2024).
Dates and value
- Award date
- Signed on Jan 23, 2019
- Ordering period ends
- Jan 24, 2024
- Ceiling
- Shared program ceiling (all awardees of this multiple-award vehicle, not a per-awardee value): $74,995,000
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Dec 17, 2024. View on USAspending · Recipient on SAM.gov
Recipient
LocationCHICAGO, IL
UEIDGBUFQYMKWB5
CAGE code03889
Business sizeOther than small businessSize at award, per the contracting officer
Organization typeCorporate tax exempt
Parent companyIIT RESEARCH INSTITUTE
Business types and certifications
Nonprofit organizationTax-exempt corporation
Self-reported at the time of the action.
Agency and place
Awarding and funding
- Awarded by
- Funded by
- Department of Health and Human Services
- National Institutes Of Health
- NIH NCI
Classification and competition
Classification
- Product or service (PSC)
- AN12HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (research and development)
Competition
- Extent competed
- Full and open competitionA
- Solicitation procedures
- Negotiated proposal/quoteNP
- Set-aside
- No set-aside used
- Contract pricing
- Order dependent (IDV allows pricing arrangement to be determined separately for each order)1
- Offers received
- 9
Solicitation and notices
- Solicitation ID
- N01CN7701918(as reported)
Contract details
- Subcontracting plan
- Individual subcontract planF
- Major program
- Prevent preclinical drug development program: preclinical efficacy&intermediate biomarkers
- Cost Accounting Standards clause
- Yes - CAS clause includedY
- Certified cost or pricing data
- No
- Service Contract Act labor standards
- No
- Commercial procedures
- Commercial products/services procedures not usedD
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not bundledH
- Consolidated requirement
- Not consolidatedD
- Undefinitized action (terms not final)
- No
- Multi-year contract
- No
- Performance-based service acquisition
- No - service where PBA is not used.N
Transaction history
Modification history
- Base award
- Jan 23, 2019
- Latest action
- Dec 17, 2024 — Other administrative actionModification P00007; administrative: no change in scope or value
- Latest substantive action
- Jun 15, 2023 — Supplemental agreement (within scope)Modification P00006
- Actions by type
- Base award1
- Other administrative action5
- New work added (outside scope)1
- Supplemental agreement (within scope)1
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Synopsized publicly (SAM.gov / FedBizOpps)
- Yes
- Simplified procedures for commercial items
- No
- A-76 (FAIR Act) action
- No
Socio-economic and policy
- Inherently governmental functions
- Other functionsOT
- Recovered materials and sustainability
- Bio-basedE
- Clinger-Cohen Act planning (IT)
- No
- Walsh-Healey Act (materials and supplies)
- Yes
Place and origin
- Domestic or foreign entity
- U.S. owned businessA
Structure
- Award or IDV
- IDV
- IDV type
- IDCB
- Indefinite-delivery contract type
- Indefinite delivery / indefinite quantityB
- Multiple or single award
- Multiple awardM
- Awarding agency code
- 7500
- Awarding sub-tier code
- 7529
- Contracting office code
- 75N910
- Transactions recorded under this award key
- 8
Funding
- Funding agency code
- 7500
- Funding sub-tier code
- 7529
- Funding office code
- 75N910